NCT03940677

Innovative Biomarkers in de Novo Parkinson's Disease

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: University Hospital, Grenoble · Academic / Other
• Sex: All
• Age: 30 Years
• Healthy volunteers: Accepted

Summary

This study aims at identifying potential new and innovative biomarkers in de novo Parkinson's disease patients. New finding will help phenotyping patients since the diagnosis of the disease and potentially also in the preclinical phase.

Detailed description

The investigators will use 4 different approaches in parallel: 1. detailed clinical evaluation using the current available validated clinical scales and the Dopamine transporter (DAT) SPECT imaging; 2. anatomical and perfusional brain evaluation using functional MRI; 3. cortical brain mapping and transcranial magnetic stimulation assessment using a robotized approach; 4. emotional responses study using a novel paradigm. These 4 modalities will be assessed at baseline, 1 year and 2 years follow-up. The investigators will integrate these 4 analysis using a mathematical paradigm in order to define specific phenotype of disease and disease progression.

Conditions

• Parkinson's Disease
• Healthy Controls Group - Age and Sex-matched

Interventions

Type	Name	Description
PROCEDURE	Brain MRI	3 Tesla brain MRI for structural and perfusion evaluation, resting state analysis and functional MRI
PROCEDURE	TMS-EEG	Transcranial magnetic stimulation (TMS) coupled with electroencephalogram (EEG) study
BEHAVIORAL	Behavioral and cognitive battery	Emotional, attentional and behavioral assessment using predefine scales and measures
OTHER	Clinical evaluation and clinical scales	Neurological evaluation, ophthalmologic assessement, Montreal cognitive assessment (MoCA), movement disorder society (MDS)- UPDRS

Timeline

• Start date: 2019-04-25
• Primary completion: 2021-12-09
• Completion: 2021-12-09
• First posted: 2019-05-07
• Last updated: 2022-05-12

Locations

1 site across 1 country: France